Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • NovoCure stock receives a “Moderate Buy” consensus rating from analysts.
  • Price targets range widely, from USD27.00 to USD34.00 amid revenue growth but persistent losses.
  • Shares recently rose 3.9%, yet remain significantly below 52-week highs.

NovoCure Limited (NASDAQ: NVCR) has drawn a varied response from analysts, as its stock continues to trade at a discount compared to its 52-week high. On Tuesday, MarketBeat Ratings reported that LADENBURG THALM/SH SH reiterated a “Buy” rating for the medical equipment company and set a USD30.00 price target, indicating a potential upside of nearly 65% from the last closing price of USD18.19.

Other brokerages, however, offered more tempered or even pessimistic outlooks. Wedbush revised its price target down to USD27.00 and maintained a “Neutral” stance. JPMorgan Chase & Co. echoed this sentiment, assigning a “Neutral” rating and lowering their target from USD29.00 to USD28.00. Wall Street Zen took a harsher view, downgrading the stock to a “Sell” in late April. In contrast, Piper Sandler maintained an “Overweight” rating with a more optimistic price target of USD34.00.

The diverging analyst opinions reflect the dual narrative around NovoCure. On the one hand, the company posted better-than-expected Q1 earnings, with a loss of USD0.31 per share compared to consensus estimates of a USD0.47 loss. Revenue for the quarter reached USD154.99 million, surpassing expectations and marking an 11.9% increase year over year. However, profitability remains elusive—NovoCure continues to operate with a negative net margin of 26.41% and a return on equity of -45.46%.

Despite encouraging revenue growth, the company’s valuation is weighed down by persistent losses and operational inefficiencies. Its P/E ratio stands at -12.05, underscoring investor concerns about future profitability. Nonetheless, the company’s relatively low debt-to-equity ratio of 0.27 and quick ratio of 1.41 suggest adequate short-term liquidity.

Market sentiment remains cautiously optimistic, with MarketBeat aggregating ratings from eight analysts: five “Buy,” two “Hold,” and one “Sell.” The average 12-month price target across analysts stands at USD32.43, suggesting substantial upside if the company can continue improving its earnings performance and reduce its operating losses.